This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. ABSTRACT: Nanomedicine Research Activity (NRA) is an extended outcome of the previously funded Drug Delivery Activity by the RCMI program. The last several years have seen significant growth in the drug delivery and pharmaceutics area at the College of Pharmacy, FAMU. The objective and mission of the drug delivery activity has been to give the scientific community at FAMU the requisite support to excel in targeted drug delivery. Currently, we have established basic infrastructure in the area of drug delivery and the future direction of this activity is to develop expertise in the emerging area of Nanomedicine by focusing specifically in the area of nanoparticles. The Long-term goal of this activity is to establish resources and expertise in the area of nanoparticle technology which could be applied to imaging of various degenerative diseases like Alzheimer and stroke and also to target various receptors in disease states like cancer and chronic fatigue syndrome.
The specific aims of this activity are:
Specific Aim 1 : Establish suitable infrastructure for nanoparticle drug delivery research by hiring key personnel and equipment.
Specific Aim 2 : To develop collaborations between research investigators with basic science and clinical backgrounds to develop innovative drug delivery technologies which can be translated from bench to bedside.
Specific Aim 3 : To develop resources and expertise for biopharmaceutical and pharmacokinetic evaluation of drugs and formulations.
Specific Aim 4 : Provide opportunities for the training of minority scientists in the area of nanoparticle formulation and delivery. These capabilities will strengthen the infrastructure and enable the investigators at historically black institutions like Florida A&M University to be able to attract extra-mural funding like R-series grants.
|Poku, Rosemary A; Salako, Olufisayo O; Amissah, Felix et al. (2017) Polyisoprenylated cysteinyl amide inhibitors induce caspase 3/7- and 8-mediated apoptosis and inhibit migration and invasion of metastatic prostate cancer cells. Am J Cancer Res 7:1515-1527|
|Ntantie, Elizabeth; Fletcher, Jerrine; Amissah, Felix et al. (2017) Polyisoprenylated cysteinyl amide inhibitors disrupt actin cytoskeleton organization, induce cell rounding and block migration of non-small cell lung cancer. Oncotarget 8:31726-31744|
|Mazzio, Elizabeth A; Soliman, Karam F A (2017) HTP Nutraceutical Screening for Histone Deacetylase Inhibitors and Effects of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed (Vitis vinifera) in HeLa cells. Cancer Genomics Proteomics 14:17-33|
|Archibong, Edikan; Foster, Alexander; Caldwell, Keirsten et al. (2016) Synthesis, characterization, and electrospinning of novel polyaniline-peptide polymers. Appl Mater Today 4:78-82|
|Ofori, Edward; Zhu, Xue Y; Etukala, Jagan R et al. (2016) Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands. Bioorg Med Chem 24:3464-71|
|Mathis, Arlesia; Rooks, Ronica; Kruger, Daniel (2016) Improving the Neighborhood Environment for Urban Older Adults: Social Context and Self-Rated Health. Int J Environ Res Public Health 13:ijerph13010003|
|Godugu, Chandraiah; Doddapaneni, Ravi; Patel, Apurva R et al. (2016) Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma. Pharm Res 33:137-54|
|Mochona, Bereket; Jackson, Timothy; McCauley, DeCoria et al. (2016) Synthesis and Cytotoxic Evaluation of Pyrrole Hetarylazoles Containing Benzimidazole/Pyrazolone/1,3,4-Oxadiazole Motifs. J Heterocycl Chem 53:1871-1877|
|Mazzio, Elizabeth A; Li, Nan; Bauer, David et al. (2016) Natural product HTP screening for antibacterial (E.coli 0157:H7) and anti-inflammatory agents in (LPS from E. coli O111:B4) activated macrophages and microglial cells; focus on sepsis. BMC Complement Altern Med 16:467|
|Etukala, Jagan R; Zhu, Xue Y; Eyunni, Suresh V K et al. (2016) Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores. Bioorg Med Chem 24:3671-9|
Showing the most recent 10 out of 204 publications